Can higher doses of oxybutynin improve efficacy in neurogenic bladder?

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 749-751

  Bennett, Nelson ^a   O'Leary, Margie ^a   Patel, Ankur S ^a   Xavier, Macrina ^a   Erickson, Janet R ^a   Chancellor, Michael B ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Liliane S Kaufman Bldg   (United States)

Author keywords

Bladder, neurogenic; Multiple sclerosis; Parkinson disease; Spinal cord injuries; Urinary incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MICTURITION; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NOCTURIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SPINAL CORD INJURY; URINE INCONTINENCE; XEROSTOMIA;

EID: 0347759842     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000103274.38694.b1     Document Type: Article

References (19)

1. Blaivas, J., Chaikin, D., Chancellor, M. B., Linsenmeyer, T., Rivas, D., Steers, W. et al: Pathophysiology of the neurogenic bladder. In: Continuum Lifelong Learning in Neurology-Neurourology. Edited by E. Mancall and T. Munsat. Baltimore: Williams & Wilkins Co., 1998
2. Watanabe, T., Vaccaro, A. R., Kumon, H., Welch, W. C., Rivas, D. A. and Chancellor, M. B.: High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol, 159: 965, 1998
3. Watanabe, T., Rivas, D. A. and Chancellor, M. B.: Urodynamics of spinal cord injury. Urol Clin North Am, 23: 459, 1996
4. Lightner, D.: Contemporary urologic management of patients with spinal cord injury. Mayo Clin Proc, 73: 434, 1998
5. Wyman, J. F.: Quality of life of older adults with urinary incontinence. J Am Geriatr Soc, 46: 778, 1998
6. Bemelmans, B. L. H., Hommes, O. R., Van Kerrebroeck, P. E. V., Lemmens, W. A. T. G., Doesburg, W. H. and Debruyne, F. M. J.: Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol, 145: 1219, 1991
7. Clark, C. M., Fleming, J. A., Li, D., Oger, J., Klonoff, H. and Paty, D.: Sleep disturbance, depression, and lesion site in patients with multiple sclerosis. Arch Neurol, 49: 641, 1992
8. Goldenberg, M. M.: An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther, 21: 634, 1999
9. Yoshimura, N., Smith, C. P., Chancellor, M. B. and de Groat, W. C.: Pharmacologic and potential biologic interventions to restore bladder function after spinal cord injury. Curr Opin Neurol, 13: 677, 2000
10. Betts, C. D., D'Mellow, M. T. and Fowler, C. J.: Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry, 56: 245, 1993
11. Gajewski, J. B. and Awad, S. A.: Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol, 135: 966, 1986
12. Thüroff, J. W., Bunke, B., Ebner, A., Faber, P., de Geeter, P., Hannappel, J. et al: Randomized, double-blind, multicenter trial on treatment of frequency, urgency and urge incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol, 145: 813, 1991
13. Zeegers, A. G. M., Kiesswetter, H., Kramer, A. E. J. L. and Jonas, U.: Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emperonium bromide and placebo. World J Urol, 5: 57, 1987
14. Gleason, D. M., Susset, J., White, C., Munoz, D. R. and Sand, P. K.: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology, 54: 420, 1999
15. Anderson, R. U., Mobley, D., Blank, B., Saltzstein, D., Susset, J., Brown, J. S. et al: Once daily controlled versus immediate release oxybutynin chloride for urge incontinence. J Urol, 161: 1809, 1999
16. Birns, J., Lukkari, E. and Malone-Lee, J. G.: A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int, 85: 793, 2000.
17. Versi, E., Appell, R., Mobley, D., Patton, W. and Saltzstein, D.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol, 95: 718, 2000
18. Gupta, S. K., Sathyan, G., Lindemulder, E. A., Ho, P. L., Sheiner, L. B. and Aarons, L.: Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther, 65: 672, 1999
19. Gupta, S. K. and Sathyan, G.: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol, 39: 289, 1999